COVID-19 treatment and glucocorticoid-induced osteoporosis: a case report
Authors:
Štambera Dalibor
Authors‘ workplace:
Kardiologická a osteologická ambulance, Kardio Znojmo s. r. o
Published in:
Clinical Osteology 2024; 29(4): 151-156
Category:
Overview
This case report describes the case of a patient treated with glucocorticoids in connection with his COVID-19 disease, who was subsequently diagnosed with glucocorticoid-induced osteoporosis (GIOP), the most common type of secondary osteoporosis today, based on densitometric findings and a history of low-strain fracture. The article highlights the need for preventive vitamin D and calcium supplementation during glucocorticoid treatment and also the need to perform whole-body densitometry at prescribed intervals in accordance with relevant recommendations.
Keywords:
calcium (Ca) – COVID-19 – densitometry – glucocorticoids – glucocorticoid-induced osteo-porosis (GIOP) – supplementation – vitamin D
Sources
Trojánek M, Grebenyuk V, Herrmannová K et al. Nový koronavirus (SARS-CoV-2) a onemocnění COVID-19. Nedatováno. Dostupné z WWW: <https://infektologie.cz/Covid2019/Covid19-CLC20.pdf>.
Štefan M, Chrdle A, Husa P et al. COVID-19: diagnostika a léčba. Nedatováno. Dostupné z WWW: <https://infektologie.cz/DPCovid21/DP5-covid-DP-podrobny-10–22.pdf>.
OECD. The impact of COVID-19 on health and health systems – OECD [24–06- 2024]. Dostupné z WWW: <https://www.oecd.org/health/COVID-19.htm>.
NHS. COVID-19-healthcare-delivery-impacts-quick-sheet.pdf. [24–06–2024]. Dostupné z WWW: <https://files.asprtracie.hhs.gov/documents/COVID-19-healthcaredelivery-impacts-quick-sheet.pdf>.
Čechům se během pandemie zhoršil zdravotní stav, odkládali návštěvu lékaře. Ministerstvo zdravotnictví. [24–06–2024]. Dostupné z WWW: <https://mzd.gov.cz/tiskove-centrum-mz/cechum-se-behem-pandemie-zhorsilzdravotni-stav-odkladali-navstevu-lekare/>.
Džupa V a Jenšovský J ed. Diagnostika a léčba osteoporózy a dalších onemocnění skeletu. Karolinum: Praha 2018. ISBN 978–80–246–3761–7.
Pikner R, Palička V, Vyskocil V et al. Definice osteoporotické (křehké) zlomeniny: stanovisko Společnosti pro metabolická onemocnění skeletu České lékařské společnosti J. E. Purkyně (SMOS ČLS JEP). Clin Osteol 2020; 25(2): 83–84.
Willers C, Norton N, Harvey NC et al. [The Scope Review Panel of the IOF]. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteopor 2022; 17(1): 1–129. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657–021–00969–8>.
Kanis JA, Cooper C, Rizzoli R et al. [Scientific advisory board of the European Society for Clinical and Economic aspects of Osteoporosis (ESCEO) and the committees of scientific advisors and national societies of the International Osteoporosis Foundation (IOF)]. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteopor Int 2019; 30(1): 3–44. Dostupné z DOI: http://dx.doi.org/10.1007/s00198–018–4704–5>
Harris K, Zagar CA, Lawrence KV. Osteoporosis: Common Questions and Answers. Am Fam Physician 2023; 107(3): 238–246.
Humphrey MB, Russell L, Danila MI et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023; 75(12): 2088–2102. Dostupné z DOI: <http://dx.doi.org/10.1002/art.42646>.
Zikán V. Glukokortikoidy Indukovaná osteoporóza. Interni Med 2007; 9(7–8): 324–327.
Evenity. Souhrn údajů o přípravku. Dostupné z WWW: <https://www.ema.europa.eu/cs/documents/product-information/evenity-epar-productinformation_cs.pdf>.
Teriparatid – SÚKL ceny a úhrady. SÚKL – Přehled léčiv. [24–06–2024]. Dostupné z WWW: <https://prehledy.sukl.cz/prehled_leciv.html#/leciva/0025491>.
Gregson C, Armstrong DJ, Bowden J et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2022; 17(1): 58. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657–022–01061–5>.
Leboff MS, Greenspan SL, Insogna KL et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2022; 33(10): 2049–2102. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–021–05900-y>.
Bayer M, Pavel Horák P, Palička V et al. Dlouhodobá léčba osteoporózy denosumabem a její přerušení: odborné stanovisko pracovní skupiny Společnosti pro metabolická onemocnění skeletu České lékařské společnosti J. E. Purkyně. Clin Osteol 2018; 23(1): 32–37.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyArticle was published in
Clinical Osteology
2024 Issue 4
Most read in this issue
- Charcot's osteoarthropathy or Sudeck's Syndrome? A case report
- Steroid contraception – the influence on bone metabolism
- Osteoporosis and liver diseases
- What's (new) in the guidelines of the osteological societies of the German-speaking countries published in 2023